References
- Stanek G, Wormser GP, Gray J, Strle F. Lyme borreliosis. Lancet 379(9814), 461–473 (2012).
- Steere AC, Livey I. Lyme disease vaccines. In: Vaccines. Plotkin SA, Orenstein WA, Offit PA (Eds). Saunders, PA, USA (2012).
- Plotkin SA. Correcting a public health fiasco: the need for a new vaccine against Lyme disease. Clin. Infect. Dis. 52(Suppl. 3), s271–s275 (2011).
- Stanek G, Fingerle V, Hunfeld KP et al. Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin. Microbiol. Infect. 17(1), 69–79 (2011).
- Nadelman RB, Wormser GP. Reinfection in patients with Lyme disease. Clin. Infect. Dis. 45(8), 1032–1038 (2007).
- CDC. Notices to Readers: Final 2011 Reports of Nationally Notifiable Infectious Diseases 61(32), 624–637 (2012).
- Lindgren E, Jaenson TGT. Lyme Borreliosis in Europe: Influences of Climate and Climate Change, Epidemiology, Ecology and Adaptation Measures. WHO, Geneva, Switzerland (2006).
- Rizzoli A, Hauffe H, Carpi G, Vourc H G, Neteler M, Rosa R. Lyme borreliosis in Europe. Euro Surveill. 16(27), pii:19906 (2011).
- Shen AK, Mead PS, Beard CB. The Lyme disease vaccine – a public health perspective. Clin. Infect. Dis. 52(Suppl. 3), s247–s252 (2011).
- Sigal LH, Zahradnik JM, Lavin P et al. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. N. Engl. J. Med. 339(4), 216–222 (1998).
- Steere AC, Sikand VK, Meurice F et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N. Engl. J. Med. 339(4), 209–215 (1998).
- Recommendations of the Advisory Committee on Immunization Practices (ACIP). Recommendations for the use of Lyme disease vaccine. MMWR Recomm. Rep. 48RR-7, 1–5 (1999).
- Poland GA. Vaccines against Lyme disease: What happened and what lessons can we learn? Clin. Infect. Dis. 52(Suppl. 3), s253–s258 (2011).
- Gross DM, Forsthuber T, Tary-Lehmann M et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 281(5377), 703–706 (1998).
- Lathrop SL, Ball R, Haber P et al. Adverse event reports following vaccination for Lyme disease: December 1998–July 2000. Vaccine 20(11–12), 1603–1608 (2002).
- Livey I, O’Rourke M, Traweger A et al. A new approach to a Lyme disease vaccine. Clin. Infect. Dis. 52(Suppl. 3), s266–s270 (2011).
- Koide S, Yang X, Huang X, Dunn JJ, Luft BJ. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA. J. Mol. Biol. 350(2), 290–299 (2005).
- Luft BJ, Dunn JJ, Lawson CL. Approaches toward the directed design of a vaccine against Borrelia burgdorferi. J. Infect. Dis. 185(Suppl. 1), S46–S51 (2002).
Websites
- CDC. Lyme Disease Data. www.cdc.gov/lyme/stats/index.html
- Phase 1/2 Lyme Vaccine Study. http://clinicaltrials.gov/ct2/show/NCT01504347